Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $2.23B |
| Gross Profit (TTM) | $-1.47B |
| EBITDA | $-2.20B |
| Operating Margin | -558.00% |
| Return on Equity | -39.00% |
| Return on Assets | -13.30% |
| Revenue/Share (TTM) | $5.66 |
| Book Value | $16.95 |
| Price-to-Book | 8.79 |
| Price-to-Sales (TTM) | 26.08 |
| EV/Revenue | 25.15 |
| EV/EBITDA | 4.64 |
| Quarterly Earnings Growth (YoY) | -85.10% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $399.24M |
| Float | $372.26M |
| % Insiders | 7.32% |
| % Institutions | 80.57% |
Volatility is currently contracting
Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent melanoma recurrence on ‘The Claman Countdown.'
Moderna consolidates after a dramatic breakout, with a bullish pennant forming near resistance and offering a potential signal for another powerful advance.
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA's upside hinges on Intismeran's ability to scale across multiple tumor types, not just melanoma. The 50/50 partnership with Merck provides both distribution strength and shared economics for Intismeran.
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
Cancer treatment name Exelixis is attempting to clear a flat base with a 57.57 pivot.
Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the stock is climbing anyway.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m.
Moderna has made an incredible comeback, surging sixfold over the past year and by around 127% over the past few weeks. The MRNA vaccine company recently announced promising news that could have major implications for its pivot toward oncology.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRNA and any ticker you trade — then tracks every position and per-strategy win rate.
